AN2 Therapeutics, Inc. (ANTX) analyst actions
Rating and price-target actions on ANTX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ANTX overview →
2 measured ANTX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease | Press release | -3.42% | -2.56% | |
| AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease | Press release | +1.53% | -12.98% |
Keep exploring
More ANTX: earnings → · SEC filings → · ANTX overview →